Armata Pharmaceuticals
ARMP
45 hedge funds and large institutions have $40.2M invested in Armata Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 3 closing their positions.
412% more capital invested
Capital invested by funds: $7.85M → $40.2M (+$32.4M)
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
25% more funds holding
Funds holding: 36 → 45 (+9)
7.29% more ownership
Funds ownership: 3.43% → 10.72% (+7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Madison Asset Management
Madison,
Wisconsin
|
+$17.7M |
| 2 |
Millennium Management
New York
|
+$1.95M |
| 3 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$711K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$624K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$513K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$252K |
| 2 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$177K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$67.7K |
| 4 |
BlackRock
New York
|
-$64.9K |
| 5 |
6CM
683 Capital Management
New York
|
-$24.1K |
ARMP Hedge Fund Activity: Q1 2026 in Review
45 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2026, worth a combined $40.2M — up 412% from $7.85M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ARMP positions and 3 closed out — a net gain of 10 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Madison Asset Management, opening a new position worth an estimated $17.7M. The largest seller was Renaissance Technologies, cutting an estimated $252K.
- 45 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2026, up from 36 in Q4 2025.
- Funds reported $40.2M of Armata Pharmaceuticals stock for Q1 2026, up 412% quarter-over-quarter.
- 13 funds opened new Armata Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +10 holders.
- The largest Armata Pharmaceuticals buyer in Q1 2026 was Madison Asset Management, an estimated $17.7M added.
- The largest Armata Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $252K sold.
Based on aggregated 13F filings for Q1 2026.